Complete Response Letter For Outlook’s Bevacizumab Is Both Straightforward And Elusive

Low On Cash, Rush Is On To Clarify US FDA’s Concerns

Paralleling the challenges of the wet AMD market it hopes to enter, the CRL for Lytenava cites manufacturing issues, which Outlook Therapeutics feels it can easily address, as well as the need for confirmatory clinical evidence, which has left the firm scrambling for a meeting with FDA.

Close up cropped shot, face of senior woman eye looking straight, into distance.
Outlook will request at Type A meeting with the FDA to discuss the CRL • Source: Shutterstock

The complete response letter for Lytenava that Outlook Therapeutics, Inc. revealed on 30 August parallels in many ways the challenges of the wet age-related macular degeneration market that firm is trying to enter with its proprietary formulation of bevacizumab: It is both straightforward and elusive.

About 50% of the wet AMD patients in the US are treated with compounded versions of I.V. bevacizumab, which leads...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Complete Response Letters

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>